Sarepta Therapeutics, Inc.
SRPT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.01 | 0.05 |
| FCF Yield | -2.22% | 13.69% | -10.13% | 0.46% |
| EV / EBITDA | -15.29 | 14.84 | -19.83 | 64.00 |
| Quality | ||||
| ROIC | -3.73% | 4.19% | -10.50% | 4.61% |
| Gross Margin | 62.25% | 75.04% | 81.53% | 79.91% |
| Cash Conversion Ratio | 0.08 | 1.33 | 1.30 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.75% | 35.23% | 31.79% | 26.80% |
| Free Cash Flow Growth | -118.67% | 136.44% | -1,266.20% | 149.98% |
| Safety | ||||
| Net Debt / EBITDA | -3.79 | 4.97 | -2.99 | 1.29 |
| Interest Coverage | -13.67 | 22.11 | -66.71 | 36.13 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.15 | 0.15 | 0.18 |
| Cash Conversion Cycle | 708.92 | 595.55 | 601.34 | 453.10 |